IP Library › Granted Patent US 10,695,331
Granted Patent B2
US 10,695,331 · App. 16/074,696 · Granted Jun 30, 2020

Veterinary composition comprising imidacloprid, moxidectin and praziquantel for cutaneous topical application (spot on), for the treatment and prevention of ecto and endoparasitoses affecting dogs

Inventors: Carlos D. Corrales (Buenos Aires República, AR); Jorge A. Dale (CABA República, AR)
Assignee: LABYES USA, LLC
A61K31/4439A61K9/0017A61K31/365A61K31/4985A61K47/10A61K47/14A61K47/18A61K47/20A61P33/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,695,331
App. No.
16/074,696
Granted
Jun 30, 2020
Kind
B2
Abstract

A monodose veterinary composition for topical application (spot on) for canines, the said composition comprising: (a) Imidacloprid, between 8.18 and 10.00%, (b) Moxidectin, between 2.86 and 3.50%, (c) Praziquantel, between 8.18 and 10.00%, and (d) an aprotic solvent selected from Dimethyl sulfoxide (DMSO), N,N-dimethylacetamide (DMAC), N,N-dimethylformamide (DMF) and their mixtures, between 65.45 and 80.00%; together with excipients acceptable from the veterinary viewpoint, where the percentages are related to the composition's total weight. The use of an effective amount of (a) Imidacloprid, (b) Moxidectin; (c) Praziquantel; and (d) an aprotic solvent selected from Dimethyl sulfoxide (DMSO), N,N-dimethylacetamide (DMAC), N,N-dimethylformamide (DMF) and mixtures of these, together with veterinary acceptable excipients, for the preparation of a monodose veterinary composition for the treatment, control and prevention of ecto and endoparasitoses in canines, where the said veterinary composition is adapted to be administered topically (spot on).

Claims (23)

1. A monodose veterinary composition consisting of:

(a) imidacloprid at a concentration of between 8.18 and 10.00%;

(b) moxidectin at a concentration of between 2.86 and 3.50%;

(c) praziquantel at a concentration of between 8.18 and 10.00%;

(d) dimethyl sulfoxide (DMSO), N,N-dimethylacetamide (DMAC), N,N-dimethylformamide (DMF), or mixtures thereof at a concentration of between 65.45 and 80.00%; and

(e) one or more excipients acceptable from a veterinary viewpoint, wherein:

each of the recited percentages is relative to the total weight of the monodose veterinary composition; and

the monodose veterinary composition is adapted for application to a canine.

2. The monodose veterinary composition according to claim 1 , wherein the one or more excipients comprises butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), thiodipropionic acid, propyl gallate, or benzyl alcohol.

3. The monodose veterinary composition according to claim 1 , wherein:

the dimethyl sulfoxide (DMSO) is present at a concentration of between 65.45 and 80.00%; and

the one or more excipients comprise:

butylhydroxyanisole (BHA) at a concentration between 0.014 and 0.017%;

butylhydroxytoluene (BHT) at a concentration between 0.006 and 0.008%;

thiodipropionic acid at a concentration between 0.041 and 0.050%;

propyl gallate at a concentration between 0.20 and 0.24%; and

benzyl alcohol, c.s.p. 100.00; and

each of the recited percentages is relative to the total weight of the monodose veterinary composition.

4. A method for treating an ectoparasite infection or an endoparasite infection comprising administering the monodose veterinary composition according to claim 1 topically (spot on) to a canine.

5. The method according to claim 4 , wherein the monodose veterinary composition is administered directly to the canine's skin, administered by immersion, administered to the canine's nape, or administered to the canine's back.

6. The method according to claim 5 , wherein:

the ectoparasite infection is caused by an organism of the species Ctenocephalides felis , an organism of the species Ctenocephalides canis , or an organism of the species Rhipicephalus sanquineus ; or

the endoparasite infection is caused by an organism of the species Ascaris spp., a larva of the species Toxocara canis , an immature adult of the species Toxocara canis , an adults of the species Toxocara canis , an organism of the species Ancylostomas spp., an organism of the species Uncinaria spp., an organism of the species Trichuris vulpis , a larva L3 of the species Dirofilaria immitis , a larva L4 of the species Dirofilaria immitis , an organism of the species Dipylidium caninum , an organism of the species Taenia taenieformis , an organism of the species Otodectes cynotis , an organism of the species Demodex canis , or an organism of the species Sarcoptes scabiei var. canis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2018
From: CORRALES, CARLOS D.; DALE, JORGE A.
To: LABYES USA, LLC
Reel/Frame 046529/0256 →
Priority Claims (1)
AR 20160101448 · May 18, 2016 · national
Continuity (1)
Related Publication 20190070158A1 · Mar 7, 2019
Cited By (1)
US 12,544,336